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Background: Although equity in health care is theoretically a cornerstone in Western societies, several studies
show that services do not always provide equitable care for immigrants. Differences in pharmaceutical consumption
between immigrants and natives are explained by variances in predisposing factors, enabling factors and needs across
populations, and can be used as a proxy of disparities in health care use. By comparing the relative differences in
pharmacological use between natives and immigrants from the same four countries of origin living in Spain and Norway
respectively, this article presents a new approach to the study of inequity in health care.
Methods: All purchased drug prescriptions classified according to the Anatomical Therapeutic Chemical (ATC) system in
Aragon (Spain) and Norway for a total of 5 million natives and nearly 100,000 immigrants for one calendar year were
included in this cross-sectional study. Age and gender adjusted relative purchase rates for immigrants from Poland, China,
Colombia and Morocco compared to native populations in each of the host countries were calculated. Direct
standardisation was performed based on the 2009 population structure of the OECD countries.
Results: Overall, a significantly lower proportion of immigrants in Aragon (Spain) and Norway purchased pharmacological
drugs compared to natives. Patterns of use across the different immigrant groups were consistent in both host countries,
despite potential disparities between the Spanish and Norwegian health care systems. Immigrants from Morocco showed
the highest drug use rates in relation to natives, especially for antidepressants, “pain killers” and drugs for peptic ulcer.
Immigrants from China and Poland showed the lowest use rates, while Colombians where more similar to host countries.
Conclusions: The similarities found between the two European countries in relation to immigrants’ pharmaceutical use
disregarding their host country emphasises the need to consider specific immigrant-related features when planning and
providing healthcare services to this part of the population. These results somehow remove the focus on inequity as the
main reason to explain differences in purchase between immigrants and natives.
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Immigration is on the rise worldwide. Immigrants from
different countries and cultures have become a natural
part of cities, villages, factories, schools and other public
spaces. Most European health care systems attempt to
ensure universal and high quality services, being equity
one of their cornerstones. But beyond the theoretical
equity in access to health care, the international litera-
ture reveals important differences in real use of host
health care systems depending on the patient’s immi-
grant status [1–7].
Pharmacological consumption can be used as a proxy
of health care utilization for epidemiological purposes
[8]. Comparisons of drug consumption rates between
immigrants and natives have seldom been conducted.
While most such studies have targeted specific drugs
[9–16], to the best of our knowledge, only a few with a
global pharmacological approach have been published
[17–20]. These studies revealed a global pattern of lower
consumption in immigrants compared with natives,
although with some exceptions [9, 10, 14]. However,
most of the studies relied on health surveys, which
often suffer from self-selection bias, especially among
immigrants [21]. Recent reviews have pointed out the
need for research based on comprehensive regional
pharmacological databases, which are not subject to
self-selection bias and allow analyses of drug purchase
both from a global perspective and for specific drugs
[4–6]. Although purchase and utilization are not ne-
cessarily equivalents, for pharmacoepidemiological
studies purchased drugs are considered a good proxy
of drug use [22] and both terms will be used inter-
changeably in this paper .
According to Andersen’s health care access model
(Fig. 1), predisposing factors, enabling factors, and needFig. 1 Factors influencing purchase of pharmacological treatment among
Adapted from Andersen’s health care access model, 1995are the three main determinants of health care use [23].
This model has previously been used for the study of
utilization of prescribed drugs [8]. Among the predisposing
factors that might explain differences in pharmacological
utilization, age, sex and other demographic disparities, gen-
etic differences, varying degrees of acculturation among
immigrants and/or different cultural traditions regarding
treatment inherent to country of origin have been described
[13, 20, 24–26]. Besides the existence and availability of
health care services, individual economic and education
levels in addition to the ability to navigate through the
health care services can enable or disable individuals to
purchase prescribed medication. Last, differences in drug
consumption between immigrants and natives can be
appropriate if different populations have different needs,
this is to say, different prevalence of diseases [27].
Until now, pharmacoepidemiological studies including
immigrants have been carried out restricted to a host
region or country. However, the host countries’ health
system regulations, ways of performance, or differential
local medical behaviours might also be considered as
enabling or disabling factors for drug prescription and
utilization [28, 29], resulting in different patterns of
prescription for immigrants depending on which country
they migrate to. For example, antidepressant consumption
could be influenced by the depression prevalence in a spe-
cific immigrant group [30] but antidepressant prescription
is also related to the host country’s approach regarding
use of psychotherapy, duration of therapy, or even to
diagnostic criteria [31]. Recently, the importance of carry-
ing out comparative studies of immigrants in several host
countries in order to clarify the influence of these factors
has been underlined [1, 32].
Following this suggestion, we investigated whether
patterns of use of pharmacological treatment forimmigrants. Study of four immigrant groups in two different countries.
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European countries: Spain and Norway. The two
countries have large immigrant populations [1], and
their health care systems deliver universal coverage
and attempt to provide equitable health care [33]. In
both countries the health systems are mainly public
and rely heavily on primary health care and general
practitioners (GPs). At the time of this study, immi-
grants and natives in Spain and Norway were equally
entitled to health care services (i.e., primary care, hospital
care, and emergency, public health, and pharmacy services).
In the case of Spain, immigrants were entitled to these ser-
vices regardless of their legal status [34], while in
Norway illegal immigrants only had access to emer-
gency health care. In Spain, users do not pay to visit the
GP and those with a prescription from the National
Health Service pay 40 % of the cost of acute medication
and 10 % of the cost of chronic medication, with a max-
imum limit of €2.64 per package. Medication is free for in-
patients and ‘exempt’ groups (i.e., retirees and those who
have disabilities or have suffered occupational accidents)
[34]. In 2010, the average copayment per patient for phar-
macy medicines prescribed by the National Health Service
was 5.6 % of the cost of the medication purchased [35]. In
the case of private prescriptions or over-the-counter
(OTC) drugs, the user must pay 100 % of the cost. It is es-
timated that of the total Spanish pharmaceutical market
handled by the Pharmacy Service in 2010, 77.3 % corre-
sponded to the Spanish National Health Service [35]. In
Norway patients visiting their GP must pay a copayment
of approximately €25 per visit. Most medications require a
prescription. Patients pay for most medications for acute ill-
nesses. Subsidised prescriptions include medications for
chronic illnesses and other non-chronic diseases that re-
quire long-term treatment in a given year and only carry a
nominal fee or copayment. Patient copayments currently
account for 36 % of total prescription costs; the total copay-
ment within a single calendar year is €240. Copayments for
physician visits, radiology examinations, and laboratory
tests are included in this amount [36]. Differences between
the two countries are also observed for pharmaceutical
costs as a percentage of health expenditure; this value is
higher in Spain [37].
Our hypothesis was that, for immigrants moving from
the same countries of origin, similar patterns of use of
pharmacological treatment would be observed in Spain
and Norway despite differences in these two countries re-
garding overall drug prescription rates. Thus, in this study
we analysed all registered pharmacological treatments in
Aragon (Spain) and Norway for immigrants from Poland,
China, Morocco and Colombia compared to natives, aim-
ing to identify patterns of drug use for all main and top 10
anatomical and therapeutic pharmacological groups for
each immigrant group compared to host country.Methods
This is a cross-sectional study comparing purchase of
pharmacological treatment in natives and immigrants in
Spain (Aragon) and Norway. The entire population from
the Aragon region (Spanish autonomous community
with approximately 1.3 million inhabitants) and the
whole registered population of Norway (approximately
4.8 million inhabitants, 12 % of them registered immi-
grants in 2008) were entitled to the respective public
health systems. The period covered by the study was 1
January to 31 December 2008 for Norway and 1 January
to 31 December 2010 for Aragon.
Immigrants were defined as persons whose birthplace
was not the host country (Spain and Norway respect-
ively), regardless of their nationality [38]. In order to en-
sure the homogeneity of study populations, only
immigrants from four countries of origin were studied,
each one from a different continent. From each contin-
ent we selected the country with the highest numbers of
immigrants common to both host countries: Poland,
China, Morocco and Colombia. Immigrant populations
as a percentage of the overall populations of Aragon and
Norway, respectively, were as follows: Poland, 0.3 and
0.9 %; Colombia, 0.8 and 1 %; China, 0.3 and 0.2 %;
Morocco, 1.5 and 0.1 %.
Data extracted for this study both in Spain and
Norway comprised all purchased drug prescriptions at
first and third level of the Anatomical Therapeutic
Chemical (ATC) system [39]. From the first ATC group
(from now on referred to as main ATC level) we ana-
lysed all the groups except the “Various” groups, as this
group comprises many different types of drugs, being
some of them for diagnostic purposes. From the third
ATC group (from now on referred to as therapeutic
ATC level), we selected the 10 most used groups of
drugs common to Norway and Aragon. Our dependent
variable was the proportion of patients having purchased
one or more drugs of a given ATC group at least once in
the study year.Spanish data
The organization and management of the Spanish National
Health care System are decentralized to the different
autonomous regions. Aragon is an autonomous region in
North-eastern Spain with 13 % of foreign nationals in 2010,
a very similar proportion to the rest of the country. The
population structure and the main characteristics of the
Aragon Health Service are also similar to those of Spain
[34]. Demographic information (age, sex and country of
birth) was extracted from the central medical database of
the Aragon Health Service. In order to match data from
both registries, a patient identification code was used to
univocally assign an anonymized number to every patient.
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from the Pharmaceutical Billing Database in Aragon.
This database covers all publicly subsidised prescription
drugs dispensed by pharmacies, and prescribed by public
practices. Drugs prescribed in private practices or those
dispensed without prescription (OTC drugs) were not
included in this study, nor were drugs used in inpatient
or outpatient hospital settings (i.e., very specific treat-
ments for particular diseases and conditions). Vaccines
were also excluded from this study.Norwegian data
Data from Norway was obtained from the National Popula-
tion Register and the Norwegian Prescription Database
(NorPD). The NorPD contains detailed information on all
prescription drugs purchased by individual people at all
pharmacies in Norway since 2004 [28]. Data are not avail-
able from either hospitals or nursing homes. Personal iden-
tification numbers assigned to all Norwegian citizens and
immigrants staying in Norway for at least six months were
used to link the registries together. Once obtained the iden-
tification number, the person is entitled to the same health
care rights disregarding his/her immigrant background.
The National Population Register provides information
about all residents in Norway. Demographic information
obtained from this database includes sex, age and country
of origin.Statistical analysis
Descriptive analyses of the selected immigrant groups
living in both countries were conducted. Sex and age-
standardised rates of purchase of selected ATC drug
groups were calculated both in Aragon and Norway
for the global populations. Direct standardisation was
performed based on the 2009 population structure of
the OECD countries [40]. Multivariable logistic re-
gression analyses were conducted to evaluate the pur-
chase odds ratios (OR) and 95 % confidence intervals
(CI) for several drug groups for each immigrant group
relative to the native population, adjusting for age
(five-year categories) and sex. The data were analysed
with the STATA statistical package (version 12) and
SPSS version 22; Excel 2010 (Microsoft Corporation)
was used for graphical design.
The study was approved by the Clinical Research Ethics
Committee of Aragon (CEICA). The Spanish part of the
present work is based on the statistical analysis of
anonymous data obtained with permission from the corre-
sponding entity. The Norwegian part of this study is framed
within the “Immigrants’ health in Norway” project, which
was approved by the Regional Committee for Medical and
Health Research Ethics and the Norwegian Data
Inspectorate.Results
We analysed drug purchase data for around 5 million
natives (Spanish and Norwegian) and for more than
96,000 immigrants. Demographic characteristics for natives
and immigrants according to their country of origin are
presented in Table 1. Overall, immigrants were younger
than host populations in both countries; differences in sex
ratios were observed depending on the immigrant’s country
of origin. Higher proportions of elderly people were found
among natives of both countries.
Table 2 shows the drug purchase rates for the main
ATC groups and the 10 most frequently used thera-
peutic ATC groups in both host countries for the whole
populations, this is to say, including natives and immi-
grants. Compared to Spain, a lower purchase rate was
observed in Norway for all main ATC groups except for
genito-urinary system and sex hormones, and for the
two less used groups: antineoplastic and immunomodu-
lating agents and antiparasitic products. Patterns were
similar at the therapeutic ATC level, with Spanish rates
two or three times higher for drugs for peptic ulcer and
gastro-oesophageal reflux disease (18.5 % [95 % CI,
18.4–18.5] vs 5.9 % [95 % CI, 5.9–5.9]), “pain-killers”
including non-steroidal anti-inflammatories and anti-
rheumatic products (34.3 % [95 % CI, 34.2–34.4] vs
17.1 % [95 % CI, 17–17.1]), other analgesics and antipy-
retics (23.5 % [95 % CI, 23.4–23.6] vs 6.0 % [95 % CI,
6.0–6.0]), and anxiolytics (11.0 % [95 % CI, 11–11.1] vs
5.7 % [95 % CI, 5.7–5.8]). Norwegians showed a higher
use of antithrombotic agents (8.7 % [95 % CI, 8.7–8.7] vs
7.1 % [95 % CI, 7.1–7.1]).
Figure 2 depicts relative drug purchase rates between im-
migrants and their respective host populations at the main
ATC levels for Spain and Norway. A high consistency of
relative use rates across immigrants from each of the four
selected countries of origin was observed in both host
countries, especially so for Chinese and Polish immigrants.
Immigrants from these two countries had significantly
lower ratios of use of all groups of medication compared to
those for natives, with most OR below 0.6 for immigrants.
A significantly higher proportion of immigrants from
Morocco purchased several drug groups compared to
natives, particularly drugs for the alimentary tract and
metabolism, dermatological, musculo-skeletal and ner-
vous systems. However, a lower share of them pur-
chased cardiovascular and antineoplasic medication.
The principal difference in relative use between Norway
and Aragon was seen for genito-urinary system and sex
hormones, which was higher only in Spain. Colombians
had lower use rates than natives in most drug groups,
especially those living in Spain. One exception was the
higher purchase rate of genito-urinary system and sex
hormones drugs for Colombians and Moroccans in
Spain. Table 3 includes additional data for the results
Table 1 Demographic characteristics of study populations
Aragon Born in Spain China Colombia Morocco Poland
n 1,102,391 3978 10,304 18,400 3169
0–14 years % 12.4 17.3 10.6 12.9 10.2
15–64 years % 64.9 80.7 87.0 84.7 89.5
65+ years % 22.8 1.9 2.4 2.4 0.3
Mean age (SD) 44.8 (23.2) 30.7 (15.2) 33.9 (14.6) 32.5 (14.4) 33.3 (13.0)
Women % 51.1 52.9 56.7 37.2 41.5
Norway Born in Norway China Colombia Morocco Poland
n 4,351,084 8386 4736 4824 42,787
0–14 years % 19.8 32.4 30.8 3.7 9.1
15–64 years % 63.9 62.5 68.3 91.9 89.4
65+ years % 16.4 5.1 0.8 4.4 1.4
Mean age (SD) 39.2 (23.9) 28.6 (19.8) 21.5 (12.9) 39.5 (13.6) 33.9 (13.6)
Women % 50.2 68.9 46.6 42.9 32
Table 2 Drug purchase rates in Spain and Norway adjusted by age and sex, including both immigrants and natives. All main
anatomical and 10 most used therapeutic ATC groups
ATC Drug Spain % (95 % CI) Norway % (95 % CI)
Main anatomical ATC groups
A Alimentary tract and metabolism 27.9 (27.8–27.9) 12.9 (12.9–13)
B Blood and blood forming organs 11.4 (11.4–11.5) 10.4 (10.4–10.5)
C Cardiovascular system 22.1 (22.0–22.2) 18.0 (17.9–18)
D Dermatologicals 15.6 (15.5–15.7) 12.1 (12.1–12.1)
G Genito-urinary system and sex hormones 6.8 (6.7–6.8) 14.6 (14.6–14.6)
H Systemic hormonal preparations, excluding sex hormones and insulins 8.3 (8.3–8.4) 7.2 (7.2–7.3)
J Antiinfectives for systemic use 32.7 (32.5–32.8) 23.7 (23.7–23.8)
L Antineoplastic and immunomodulating agents 1.1 (1.0–1.1) 1.4 (1.4–1.41)
M Musculo-skeletal system 38 (37.9–38.1) 18.5 (18.5–18.6)
N Nervous system 35.2 (35.14–35.4) 24.5 (24.4–24.5)
P Antiparasitic products, insecticides and repellents 0.8 (0.8–0.9) 1.9 (1.8–1.9)
R Respiratory system 33.9 (33.8–34) 23.7 (23.6–23.7)
S Sensory organs 15.4 (15.3–15.4) 12.1 (12.1–12.2)
Main therapeutic ATC groups
A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease 18.5 (18.4–18.5) 5.9 (5.9–5.9)
B01A Antithrombotic Agents 7.1 (7.1–7.1) 8.7 (8.7–8.7)
C10A Lipid modifying agents 9.8 (9.7–9.8) 8.3 (8.3–8.3)
J01C Beta-lactam antibacterials, penicillins 20.4 (20.3–20.6) 15.7 (15.7–15.8)
J01F Macrolides, lincosamides and streptogramins 7.3 (7.3–7.4) 6.4 (6.4–6.5)
M01A Antiinflammatory and antirheumatic products, non-steroids 34.3 (34.2–34.4) 17.1 (17–17.1)
N02B Other analgesics and antipyretics 23.5 (23.4–23.6) 6.0 (6.0–6.0)
N05B Anxiolytics 11.0 (11–11.1) 5.7 (5.7–5.8)
N06A Antidepressants 7.0 (6.9–7.0) 5.9 (5.8–5.9)
R06A Antihistamines for systemic use 11.2 (11.1–11.3) 10.7 (10.7–10.7)
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China Colombia Morocco Poland
Fig. 2 Relative drug purchase rates (main ATC groups) for immigrants from China, Colombia, Morocco and Poland in Spain and Norway compared
with the native population. Odds ratios and 95 % confidence intervals adjusted by age and sex
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and 95 % confidence interval).
Figure 3 presents relative drug purchase rates for im-
migrants compared to their host populations for the 10most frequently used drugs at the third therapeutic ATC
level. In this case, again, most immigrants’ purchase
rates were significantly lower for all drug groups in
Norway and Spain. Moroccans presented higher use
Table 3 Relative drug purchase rates (main ATC groups) for immigrants from China, Colombia, Morocco and Poland in Spain and
Norway compared with the native population. Odds ratios and 95 % confidence intervals adjusted by age and sex
Drug Host country China Colombia Morocco Poland
Alimentary tract and metabolism Spain 0.54 (0.49–0.59) 0.87 (0.83–0.92) 1.13 (1.09–1.17) 0.33 (0.29–0.37)
Norway 0.65 (0.59–0.71) 0.97 (0.86–1.11) 1.71 (1.58–1.84) 0.35 (0.33–0.36)
Blood and blood forming organs Spain 0.59 (0.51–0.69) 0.91 (0.84–0.98) 1.09 (1.03–1.15) 0.47 (0.39–0.56)
Norway 0.45 (0.39–0.52) 0.77 (0.61–0.98) 0.63 (0.55–0.72) 0.34 (0.31–0.37)
Cardiovascular system Spain 0.39 (0.33–0.45) 0.72 (0.68–0.78) 0.65 (0.61–0.69) 0.46 (0.39–0.53)
Norway 0.55 (0.50–0.61) 0.69 (0.57–0.83) 0.70 (0.63–0.77) 0.35 (0.33–0.37)
Dermatologicals Spain 0.60 (0.54–0.67) 0.91 (0.86–0.96) 1.16 (1.11–1.21) 0.35 (0.3–0.41)
Norway 0.81 (0.75–0.87) 0.88 (0.80–0.97) 1.09 (1.00–1.18) 0.32 (0.3–0.33)
Genito-urinary system and sex hormones Spain 0.50 (0.41–0.61) 1.49 (1.38–1.60) 1.79 (1.70–1.89) 0.57 (0.46–0.71)
Norway 0.28 (0.26–0.31) 0.80 (0.73–0.88) 0.70 (0.63–0.76) 0.26 (0.25–0.27)
Systemic hormonal preparations, excluding
sex hormones and insulins
Spain 0.43 (0.37–0.51) 0.67 (0.61–0.73) 0.79 (0.75–0.85) 0.42 (0.35–0.51)
Norway 0.47 (0.42–0.54) 1.06 (0.92–1.23) 0.87 (0.77–0.98) 0.3 (0.28–0.33)
Antiinfectives for systemic use Spain 0.29 (0.26–0.31) 0.57 (0.55–0.60) 0.84 (0.81–0.86) 0.4 (0.36–0.43)
Norway 0.44 (0.41–0.47) 0.89 (0.83–0.96) 0.92 (0.86–0.98) 0.35 (0.33–0.36)
Antineoplastic and immunomodulating agents Spain 0.12 (0.04–0.36) 0.61 (0.46–0.82) 0.47 (0.37–0.61) 0.24 (0.1–0.57)
Norway 0.40 (0.27–0.56) 1.05 (0.71–1.54) 0.53 (0.38–0.75) 0.23 (0.19–0.28)
Musculo-skeletal system Spain 0.32 (0.29–0.35) 0.75 (0.72–0.78) 1.15 (1.11–1.18) 0.38 (0.34–0.41)
Norway 0.39 (0.36–0.43) 0.96 (0.88–1.06) 1.18 (1.10–1.26) 0.33 (0.32–0.34)
Nervous system Spain 0.36 (0.33–0.40) 0.73 (0.70–0.77) 1.13 (1.09–1.16) 0.37 (0.33–0.41)
Norway 0.29 (0.27–0.32) 1.29 (1.19–1.39) 1.36 (1.28–1.45) 0.31 (0.3–0.32)
Antiparasitic products, insecticides and repellents Spain 0.41 (0.25–0.68) 0.94 (0.76–1.16) 1.15 (0.99–1.33) 0.33 (0.17–0.64)
Norway 0.53 (0.43–0.67) 1.35 (1.11–1.64) 0.88 (0.71–1.08) 0.34 (0.3–0.38)
Respiratory system Spain 0.40 (0.37–0.44) 0.56 (0.53–0.59) 0.63 (0.61–0.65) 0.28 (0.25–0.31)
Norway 0.64 (0.61–0.70) 1.11 (1.04–1.19) 0.92 (0.86–0.99) 0.25 (0.24–0.26)
Sensory organs Spain 0.45 (0.40–0.51) 0.69 (0.65–0.74) 0.93 (0.88–0.97) 0.21 (0.17–0.26)
Norway 0.67 (0.62–0.72) 1.15 (1.05–1.26) 1.09 (1.01–1.20) 0.28 (0.26–0.29)
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reflux disease, non-steroids anti-inflammatory and anti-
rheumatic products and other analgesics and antipy-
retics, and anxiolytics in both host countries, and higher
antidepressant purchase rates in Norway whilst lower in
Spain. Colombians presented lower or similar rates ex-
cept for antihistamines for systemic use in Norway. As it
happened for the main ATC levels, there was high
consistency across the relative use rates of most drug
groups in Norway and in Spain, especially so for Polish
and Chinese immigrants. Table 4 includes additional
data for the results shown in Fig. 3 (data are expressed
as the odds ratio and 95 % confidence interval).
Discussion
In the two European countries studied, Spain and Norway,
the proportion of immigrants that purchased pharmaco-
logical drugs was significantly lower than that of the
corresponding native population. Patterns of use acrossthe different immigrant groups were consistent in both
host countries, despite potential disparities in prescription
habits and other differences between the Spanish and
Norwegian health care systems. Immigrants from Morocco
showed the highest drug purchase rates in relation to
natives, especially for antidepressants, “pain killers” and
drugs for peptic ulcer. Immigrants from China and
Poland showed lowest purchasing rates, while Colombians
where more similar to host countries.
Although our study cannot explain the reasons for the
lower use rates of the Polish and Chinese and the higher
rates among Moroccans, previous studies have revealed a
lower morbidity burden in patients from Asia and Eastern
Europe and a worse health profile in African immigrants
[27, 41, 42], and similar results have been found regarding
life expectancy and mortality [43, 44]. Our results could
thus be related to a better health status and consequently
lower drug need in the case of Polish and Chinese
immigrants and to worse health and higher purchase in
China Colombia Morocco Poland
Fig. 3 Relative drug purchase rates (ten most used therapeutic ATC groups) for immigrants from China, Colombia, Morocco and Poland in Spain
and Norway compared with the native population. Odds ratios and 95 % confidence intervals adjusted by age and sex
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bidity burden could test this hypothesis in further studies.
Global prescription rates in Norway and Spain differed
significantly. Accordingly, similar use patterns across
immigrants living in both host countries cannot be
completely explained by differences in need (prevalence
of illness) between natives and immigrants. Following
Andresen’s model (Fig. 1), we compared the same four
immigrant groups and adjusted for age and sex in order
to reduce some of the differences in predisposing factors
affecting the purchase of medication by immigrants in
Spain and Norway. However, although the genetics and
traditions of the different immigrant groups are probably
the same regardless of the country they move to, other
factors such as acculturation may present less of a chal-
lenge in one host country compared to another (e.g., forColombians in Spain, given their common language) [8,
11, 24, 25]. Nonetheless, the pattern observed for
Colombian immigrants in Spain was no closer to the
native pattern than that observed in Norway. Informa-
tion regarding length of stay in the host country was
unfortunately unavailable for this study, but could have
helped us to determine wheter patterns changed with
time since migration; several studies have demonstrated
that health problems and health care utilization in-
crease with time spent in the host country [32, 41].
As regard to predisposing factors, reasons for migration
might be different in Moroccans and Colombians who
decided to migrate to Norway, a country with a relatively
high proportion of refugees, or to Spain, where most
immigrants are labour ones. Our findings concerning
antidepressant medication, which was significantly more
Table 4 Relative drug purchase rates (ten most used therapeutic ATC groups) for immigrants from China, Colombia, Morocco and
Poland in Spain and Norway compared with the native population. Odds ratios and 95 % confidence intervals adjusted by age and sex
Drug Host country China Colombia Morocco Poland
Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease Spain 0.63 (0.55–0.71) 1.02 (0.96–1.09) 1.24 (1.18–1.30) 0.37 (0.32–0.44)
Norway 0.83 (0.73–0.94) 1.12 (0.94–1.35) 1.58 (1.43–1.76) 0.45 (0.42–0.48)
Antithrombotic Agents Spain 0.22 (0.15–0.32) 0.51 (0.44–0.60) 0.56 (0.51–0.63) 0.36 (0.25–0.50)
Norway 0.50 (0.43–0.58) 0.67 (0.47–0.94) 0.51 (0.43–0.61) 0.36 (0.33–0.39)
Lipid Modifying Agents, Plain Spain 0.26 (0.20–0.34) 0.67 (0.61–0.74) 0.43 (0.39–0.47) 0.23 (0.17–0.31)
Norway 0.46 (0.40–0.54) 0.70 (0.50–0.97) 0.59 (0.50–0.69) 0.33 (0.30–0.36)
Beta-Lactam Antibacterials, Penicillins Spain 0.30 (0.27–0.33) 0.52 (0.49–0.55) 0.87 (0.83–0.90) 0.45 (0.40–0.50)
Norway 0.46 (0.42–0.50) 0.86 (0.79–0.94) 1.04 (0.97–1.13) 0.39 (0.38–0.41)
Macrolides, Lincosamides And Streptogramins Spain 0.29 (0.24–0.36) 0.55 (0.50–0.61) 0.59 (0.55–0.63) 0.35 (0.28–0.43)
Norway 0.46 (0.41–0.52) 0.88 (0.78–0.99) 0.72 (0.63–0.82) 0.33 (0.31–0.35)
Antiinflammatory and Antirheumatic Products, Non-Steroids Spain 0.32 (0.30–0.35) 0.78 (0.75–0.82) 1.18 (1.15–1.22) 0.40 (0.36–0.44)
Norway 0.39 (0.35–0.42) 0.96 (0.87–1.05) 1.19 (1.11–1.27) 0.33 (0.32–0.34)
Other Analgesics and Antipyretics Spain 0.49 (0.44–0.54) 0.78 (0.74–0.82) 1.49 (1.44–1.54) 0.42 (0.37–0.48)
Norway 0.42 (0.35–0.50) 0.88 (0.71–1.09) 1.49 (1.33–1.67) 0.39 (0.36–0.43)
Anxiolytics Spain 0.27 (0.22–0.33) 0.64 (0.59–0.70) 0.63 (0.59–0.68) 0.38 (0.31–0.46)
Norway 0.29 (0.24–0.35) 0.87 (0.71–1.07) 0.89 (0.78–1.01) 0.37 (0.34–0.40)
Antidepressants Spain 0.08 (0.05–0.12) 0.55 (0.49–0.61) 0.54 (0.49–0.59) 0.25 (0.19–0.35)
Norway 0.27 (0.22–0.33) 1.13 (0.97–1.33) 2.28 (2.10–2.48) 0.32 (0.29–0.34)
Antihistamines For Systemic Use Spain 0.68 (0.61–0.76) 0.86 (0.81–0.92) 0.83 (0.79–0.87) 0.31 (0.26–0.37)
Norway 0.84 (0.78–0.90) 1.32 (1.22–1.44) 1.03 (0.94–1.12) 0.18 (0.17–0.19)
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living in Norway compared to those living in Spain, has
been previously described separately for each country
[13, 14], and could reflect different reasons for migra-
tion in persons from the same country depending on
the country they move to, as refugees have a higher
prevalence of psychiatric illness compared to other im-
migrants [45].
Health care services and pharmacological treatment
were largely free for immigrants who were entitled to
public health care in both Spain and Norway at the time
of the study. Therefore, apart for availability of services,
other enabling or disabling factors like service’s friendly
navigability and/or the ability or desirability to use the
host country’s health services are probably essential
factors determining the patterns of drug purchase
among immigrants. Self-medication, which is extended
among the Polish [46, 47], could explain their pattern of
purchase in Spain and Norway if they buy medication
when visiting their country on vacation [48]. Chinese
people, on the other side, are known for using traditional
medication [49] that might be available in the host
countries and would not be registered in the ATC sys-
tem. Unfortunately, we could not adjust our data for
income and education levels, which might account for
differences between groups to some extent.Our analysis of four immigrant groups from different
parts of the world, each with similar predisposing factors
and needs, living in two European countries offering
similar healthcare coverage, revealed medication pur-
chasing profiles that were relatively consistent for each
immigrant population. The purchase rates for most of
these groups were lower than those of the host popula-
tions, which may be indicative of health care barriers for
immigrants in both Spain and Norway. However, while
the possibility of differences in health care equity cannot
be ruled out, our results point to intrinsic differences
between immigrant groups, suggesting that inequity is
not the main driver of the observed differences in pur-
chasing rates between immigrants and natives.Strenghts and limitations
This is a large population-based study including more
than five millions natives and around 100,000 immi-
grants. Given the large sample size, most of the differ-
ences are statistically significant, although some of them
are small and may not be clinically or socially relevant
[50]. The information was obtained from electronic pre-
scription databases, a source of information that has
demonstrated a high value to study the epidemiology of
drug use [14, 28, 50]. The use of linked registries avoids
Gimeno-Feliu et al. International Journal for Equity in Health  (2016) 15:32 Page 10 of 11self-selection bias, which typically endangers the external
validity of studies on immigrant health.
Several limitations of our approach should be noted.
We did not include OTC prescriptions, which could be
potentially important in the case of specific drugs (e.g.,
painkillers. A study by Carrasco-Garrido and coworkers
found that 23.1 % of Spaniards had used OTC drugs
within the previous two weeks, compared with 18.1 % of
the immigrant population [17]. Inclusion of these data
would only increase the differences in drug consumption
between native and immigrant populations in Spain.
Moreover, we analysed annual purchase rates as opposed
to the annual amount of drugs. Accordingly, extra medi-
cation bought over the counter should not significantly
alter our results. Drug prescriptions from private doctors
are not registered in the Aragon Pharmacy Database, but
are registered in Norway. One potential implication of
this difference is the exclusion of the large number of
prescriptions for hormonal birth control provided by
private gynaecologists to Spanish natives, which may ex-
plain the higher relative rate of consumption of genito-
urinary system drugs and sex hormones in Moroccan
and Colombian women in Spain, but not in Norway. Be-
cause Spaniards are more likely to have private health
insurance (17.4 %) than immigrants (12.6 %) [51], inclu-
sion of this data would further widen the gap in drug
consumption between immigrants and natives in Spain.
Prescriptions for patients in nursing homes were not
available in the datasets analysed, which may partially ex-
plain the lower general purchase rates in Norway, where
this phenomenon is more common than in Spain. How-
ever, this applies to individuals of 80 years and older, an
age range that emcopasses very few immigrants. Because
our study was focused on the relative differences within
each host country, the impact of this potential under-
registration on our overall findings is lessened.
A general problem using purchased data to assess drug
use is also the fact that we do not know if and when the dis-
pensed drugs are actually ingested by the patients [28].
However, in pharmacoepidemiological studies purchased
drugs are considered a good proxy of drug use [22]. Another
limitation could be the different years of data provenance:
2010 in the case of Spain and 2008 in Norway. Taking into
account that our study compares the relative purchase rates
between immigrants and natives within each country, this
fact should not affect the final results. Last, we defined im-
migrants as persons born abroad (from Spain or Norway).
Using other definitions, like nationality, would have changed
results because of differences in nationalization laws in
Spain and Norway. For example in Spain an immigrant
needs to have lived at least 10 years in the country before
he/she can apply for the Spanish nationality, but this period
of time is much shorter if the immigrant comes from Latin
American countries. On the other hand, in Norway thenationalization process can be very short in the case of
refugees. Our choice sought to minimise this possible
misclassification.
Conclusions
The similarities found between the two European countries
in relation to immigrants’ pharmaceutical use disregarding
their host country, emphasises the need to consider specific
immigrant-related features when planning and providing
health care services to this part of the population.
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